Second-line treatment of hepatocellular carcinoma: from theory to practical issues
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with unmet needs of effective medications. Lenvatinib – a new oral multikinase inhibitor (MKI) proved to be as effective as sorafenib in terms of survival has been added recently to standard first-line treatment of advanced HCC...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5058 |